The immunogenic properties of drug-resistant murine tumor cells do not correlate with expression of the MDR phenotype.
Alterations in the immunogenic properties of tumor cells frequently accompany selection for multiple-drug-resistant (MDR) variants. Therefore, studies were performed to examine the hypothesis that overexpression of membrane P-glycoprotein, commonly observed in MDR tumor cells, is associated with enhanced immunogenic properties. Immunogenicity was determined by (a) the ability of drug-sensitive parental UV2237M fibrosarcoma cells and drug-resistant UV2237M variant cells to immunize normal mice against rechallenge with parental tumor cells and (b) the ability of normal syngeneic mice to reject cell inocula that caused progressive tumor growth in immunocompromised mice. Variant UV2237M cell lines included subpopulations selected for a six- to ten-fold increase in mRNA for P-glycoprotein and expression of the MDR phenotype (resistance to doxorubicin) and cells sensitive to doxorubicin (and no expression of MDR properties) but resistant to ouabain. All UV2237M drug-resistant cells were highly immunogenic in immunocompetent mice, regardless of their MDR phenotype. Additional studies showed that CT-26 murine adenocarcinoma cells, sensitive or resistant to doxorubicin (expressing high levels of P-glycoprotein), injected into normal syngeneic Balb/c mice produced rapidly growing tumors. The data do not demonstrate a correlation between the immunogenic properties of drug-resistant tumor cells and the expression of P-glycoprotein.
Killion
J J
JJ
Department of Cell Biology, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Radinsky
R
R
Dong
Z
Z
Fishbeck
R
R
Whitworth
P
P
Fidler
I J
IJ
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000230:Adenocarcinoma / Q000188:drug therapy / Q000276:immunology*; D000818:Animals; D002352:Carrier Proteins / Q000235:genetics*; D004317:Doxorubicin / Q000627:therapeutic use; D004351:Drug Resistance / Q000235:genetics*; D005354:Fibrosarcoma / Q000188:drug therapy / Q000276:immunology*; D008562:Membrane Glycoproteins / Q000235:genetics*; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008819:Mice, Nude; D010042:Ouabain / Q000627:therapeutic use; D010641:Phenotype; D012513:Sarcoma, Experimental / Q000188:drug therapy / Q000276:immunology*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D002352:Carrier Proteins; D008562:Membrane Glycoproteins; D010042:Ouabain; D004317:Doxorubicin